UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma

The oncologist (Dayton, Ohio), 2021-03, Vol.26 (3), p.e484-e491

2021

Volltextzugriff (PDF)

Mental health issues among Indian women during the COVID-19 pandemic driven lockdown

Journal of current research in scientific medicine, 2022-01, Vol.8 (1), p.89-90

2022

Volltextzugriff (PDF)

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

Clinical cancer research, 2015-12, Vol.21 (23), p.5205-5208

2015

Volltextzugriff (PDF)

Awareness and healthcare-seeking behavior regarding acute respiratory infections among mothers of under-five children in rural Tamil Nadu: A hospital-based cross-sectional study

Journal of current research in scientific medicine, 2024-04

2024

Volltextzugriff (PDF)

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Clinical cancer research, 2022-12, Vol.28 (24), p.5249-5253

2022

Volltextzugriff (PDF)

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Clinical cancer research, 2022-10, Vol.28 (19), p.4173-4177

2022

Volltextzugriff (PDF)

U.S. FDA analysis of enrollment of Asian patients from India in cancer clinical trials leading to approval from 2010 to 2022

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13779-e13779

2024

Volltextzugriff (PDF)

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma

Clinical cancer research, 2021-08, Vol.27 (15), p.4142-4146

2021

Volltextzugriff (PDF)

FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response

Clinical cancer research, 2023-02, Vol.29 (3), p.685-685

2023

Volltextzugriff (PDF)

Prevalence of Anemia among Adolescent Girls in Rural Area of a District of Maharashtra

Indian journal of community health, 2023-01, Vol.35 (1), p.21-26

2023

Volltextzugriff (PDF)

FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors

Clinical cancer research, 2023-09, Vol.29 (18), p.3573-3578

2023

Volltextzugriff (PDF)

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

Clinical cancer research, 2021-05, Vol.27 (9), p.2416-2423

2021

Volltextzugriff (PDF)

Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs

The oncologist (Dayton, Ohio), 2020-04, Vol.25 (4), p.348-354

2020

Volltextzugriff (PDF)

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical cancer research, 2023-02, Vol.29 (3), p.508-512

2023

Volltextzugriff (PDF)

Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types

Value in health, 2021-09, Vol.24 (9), p.1302-1307

2021

Volltextzugriff (PDF)

FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data

Clinical cancer research, 2023-08, Vol.29 (16), p.2964-2972

2023

Volltextzugriff (PDF)

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Clinical cancer research, 2023-09, Vol.29 (18), p.3573-3578

2023

Volltextzugriff (PDF)

FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs

Clinical cancer research, 2021-02, Vol.27 (4), p.916-921

2021

Volltextzugriff (PDF)

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

The Lancet. Haematology, 2022-05, Vol.9 (5), p.e374-e384

2022

Volltextzugriff (PDF)

Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs

The oncologist (Dayton, Ohio), 2019-12

2019

Volltextzugriff (PDF)

Study of nutritional status of adolescent girls in a rural area of a district of Maharashtra

International Journal Of Community Medicine And Public Health, 2017-11, Vol.4 (12), p.4617

2017

Volltextzugriff (PDF)

The maze of PARP inhibitors in ovarian cancer

Oncology (Williston Park, N.Y.), 2012-02, Vol.26 (2), p.136-137

2012

Volltextzugriff (PDF)

Reaching Beyond Maximum Grade: Progress and Future Directions for Modernizing the Assessment and Reporting of Adverse Events in Haematological Malignancies: Lancet Haematology Commission Follow Up

The Lancet. Haematology, 2022-05, Vol.9 (5), p.e374-e384

2022

Volltextzugriff (PDF)

Study of maternal mortality in a tertiary care hospital in a district of Maharashtra

International journal of medical science and public health, 2016, Vol.5 (9), p.1851

2016

Volltextzugriff (PDF)

Assessment of maternal risk factors associated with low birth weight neonates at a tertiary hospital, Nanded, Maharashtra

Nigerian medical journal, 2016-01, Vol.57 (1), p.37-43

2016

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(37)
Buchkapitel
(3)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(24)
Humans
(17)
Oncology
(15)
Adult
(5)
Female
(5)
United States
(5)
Male
(4)
Child
(3)
Drug Approval
(3)
Health Aspects
(3)
Rheumatology
(3)
Thyroid Neoplasms - Drug Therapy
(3)
Adenocarcinoma - Pathology
(2)
Adolescent
(2)
Antibodies
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Cancer
(2)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(2)
Carcinoma, Non-Small-Cell Lung - Genetics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma

Mental health issues among Indian women during the COVID-19 pandemic driven lockdown

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer

Awareness and healthcare-seeking behavior regarding acute respiratory infections among mothers of under-five children in rural Tamil Nadu: A hospital-based cross-sectional study

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

U.S. FDA analysis of enrollment of Asian patients from India in cancer clinical trials leading to approval from 2010 to 2022

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma

FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response

Prevalence of Anemia among Adolescent Girls in Rural Area of a District of Maharashtra

FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types

FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs

Study of nutritional status of adolescent girls in a rural area of a district of Maharashtra

The maze of PARP inhibitors in ovarian cancer

Reaching Beyond Maximum Grade: Progress and Future Directions for Modernizing the Assessment and Reporting of Adverse Events in Haematological Malignancies: Lancet Haematology Commission Follow Up

Study of maternal mortality in a tertiary care hospital in a district of Maharashtra

Assessment of maternal risk factors associated with low birth weight neonates at a tertiary hospital, Nanded, Maharashtra

Suchergebnisse filtern